pharmaphorum

JULY 5, 2022

The new partnership will apply Mogrify’s cellular reprogramming and bioinformatics expertise to try to identify transcription factors – proteins which can turn specific genes on or off – that can be used to generate new cochlear hair cells. An estimated 1.57

In-Vivo 110

In-Vivo Bioinformatics Genetics Licensing 110

Drug Discovery World

OCTOBER 26, 2023

The technologies cover the whole range of biomolecules from genes to protein to metabolites. With the ability to analyse thousands of proteins simultaneously, proteomics empowers scientists to reveal previously unknown protein interactions, pathways, and drug targets. phosphorylations or ubiquitinations).

Drugs 52

Drugs Protein Genome Genomics 52

Drug Discovery World

OCTOBER 20, 2023

The latest acquisitions and strategic partnerships in the drug discovery and development sector reveal the areas where companies predict significant growth in the near future: proteomics, CAR-T, antibody discovery, artificial intelligence (AI) and microbiomics. Olink specialises in solutions for proteomics discovery and development.

Drugs 52

Drugs Antibody DNA Gene Therapy 52

Drug Discovery World

JULY 11, 2023

Drug discovery and development timelines can span 10-15 years or more from initial discovery to market approval and typically require the analysis of massive amounts of data. How AI and ML are influencing drug development Biopharma has experienced significant growth in using these technologies for the past 10 years.

Big Data 40

Big Data Development Life Science Drugs 40

Scienmag

OCTOBER 27, 2020

Scientists from the iMolecule group at Skoltech Center for Computational and Data-Intensive Science and Engineering (CDISE) developed BiteNet, a machine learning (ML) algorithm that helps find drug binding sites, i.e. potential drug targets, in proteins. BiteNet can analyze 1,000 protein structures in 1.5

Drugs 59

Drugs Protein Engineer Scientist 59

pharmaphorum

APRIL 1, 2021

We speak to the company’s CEO and co-founder, Szabolcs Nagy, to find out why moving beyond traditional biotech drug development is a good fit for the country’s ecosystem. For example, you can simulate what would happen if you inhibited thousands of different proteins in thousands of different cell models.”. So what do they do?

Bioinformatics 123

Bioinformatics Drugs Development Scientist 123

Drug Discovery World

APRIL 6, 2023

These topics will be represented across a range of session types, including methods workshops, minisymposia, poster and plenary sessions, as well as keynotes, awards and lectures.

Protein 52

Protein Clinical Trials Clinical Trials Antibody 52

Scienmag

JULY 1, 2021

Almost twenty years ago, the process of RNA silencing was discovered in plants, whereby small fragments of RNA inactivate a portion of a gene during protein synthesis.

RNA 60

RNA Protein Research Gene 60

pharmaphorum

OCTOBER 20, 2021

A software platform developed by Altoida that uses augmented reality and artificial intelligence to diagnose neurological diseases in their earliest stages is being tested in a five-year trial involving thousands of patients.

Trials 78

Trials Genome Genomics Bioinformatics 78

Drug Discovery World

OCTOBER 7, 2022

To investigate the immune environment that surrounds these chemotherapy-resistant tumours, the researchers employed multiple and novel complementary technologies looking at proteins and genes on both pre-treatment and post-treatment breast cancer tissue. Developing immunotherapies for high-risk breast cancer patients.

Research 52

Research Immune Response Gene Bioinformatics 52

Scienmag

AUGUST 11, 2020

Researchers from Skoltech, Lomonosov Moscow State University, and the Kharkevich Institute for Information Transmission Problems have studied the genomes of some 200 strains of bacteria to determine which proteins in the ribosome, part of the key cell machinery, can be safely lost and why.

Bacteria 41

Bacteria Genome Genomics Protein 41

STAT News

MARCH 6, 2023

Cambridge-based Moderna recently reported encouraging results from a study of another type of personalized cancer vaccine it developed with the pharmaceutical giant Merck; it uses messenger RNA technology to target advanced melanoma. Neoantigen vaccines are designed to target certain proteins called neoantigens on tumor cells.

Vaccination 98

Vaccination Vaccine Drugs Clinical Trials 98

The Pharma Data

JULY 27, 2021

Amgen (NASDAQ: AMGN) and Teneobio today announced an agreement under which Amgen will acquire Teneobio, a privately held, clinical stage biotechnology company developing a new class of biologics called Human Heavy-Chain Antibodies. executive vice president of Research and Development at Amgen. billion in cash. Reese, M.D.,

Production 52

Production Antibody Sales Manufacturing 52

Drug Discovery World

NOVEMBER 13, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Ali Madani, PhD, Founder and CEO, Profluent Bio, on: ‘Protein engineering with large language models’.

Protein 59

Protein Antibody Engineer Scientist 59

Drug Discovery World

APRIL 14, 2023

He is being recognised for his revolutionary contributions to developing the first gene-edited cell-based therapy for cancer that involves the genetic re-engineering of a patient’s own T cells to combat their disease, and for demonstrating that adoptive T-cell therapy can induce remission and in some cases cure patients with advanced cancer.

Genetics 52

Genetics Research Medicine Clinical Research 52

Drug Discovery World

NOVEMBER 9, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Gail Calvert, Field Application Scientist, Sartorius UK, on: ‘Leveraging integrated and advanced technologies for successful cell line development’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

Drug Discovery World

NOVEMBER 8, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting.

Antibody 64

Antibody Engineer Protein Scientist 64

Drug Discovery World

APRIL 14, 2023

DDW Editor Reece Armstrong speaks to Nautilus Co-Founder and Chief Scientist Parag Mallick , about the company’s recent collaboration which aims to uncover the proteins that could be behind a rare and fatal childhood cancer. To do this, Nautilus will useits protein analysis platform to provide TGen with data on the proteins involved in DPIG.

Protein 52

Protein Genome Genomics DNA 52

Drug Discovery World

NOVEMBER 30, 2023

Lightcast is developing a novel, programmable microfluidic platform that allows precise and highly flexible control of individual microdroplets using software-generated light patterns. This presentation covered three primary drivers for a protein expression model: speed, cost and sustainability. “It

Antibody 59

Antibody Protein Engineer In-Vivo 59

XTalks

DECEMBER 13, 2023

In 2023, biotechnology and pharmaceutical companies leverage cutting-edge technology and significant investments in research and development (R&D) to continue pushing the boundaries of innovation in the healthcare sector, transcending the challenges posed by the pandemic.

Genetics 111

Genetics Vaccination Vaccine DNA 111

XTalks

NOVEMBER 7, 2022

In addition, Dr. Bahassi stressed that the simple enumeration of CTCs will not contribute significantly to the development of improved or more personalized cancer treatments. During the webinar, Dr. Bahassi gave a brief schematic of how personalized, targeted assays can be developed to detect somatic mutations from cfDNA ( Figure 1 ).

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

Drug Discovery World

FEBRUARY 6, 2023

Johannes Goll, Global Head of Emmes’ Biomedical Data Science and Bioinformatics department, explains how big data analytics can deliver improved therapies and bring clinical research one step close to realising the potential of personalised care. Figure 2: Advanced data visualisation examples for transcriptomics data.

Big Data 52

Big Data RNA Bioinformatics Vaccination 52

Drug Discovery World

NOVEMBER 15, 2022

Known for its ability to offer precision and flexibility while expanding the experimental scale, synthetic biology tools can reduce development timelines and costs, and lend a competitive advantage over traditional methods. . Here we outline four synthetic biology approaches that are improving and accelerating drug discovery: .

DNA 98

DNA Drugs Antibody Engineer 98

The Pharma Data

SEPTEMBER 1, 2020

head of Immunology and Fibrosis Development, Bristol Myers Squibb. Pregnancy outcomes in the ozanimod multiple sclerosis clinical development program. Inhibition of drug transporter breast cancer resistance protein has no effect on the pharmacokinetics of major active metabolites of ozanimod. Author: Minton. Author: Harris.

Trials 52

Trials Clinical Trials Clinical Trials Vaccination 52

Drug Discovery World

NOVEMBER 4, 2022

In order to design novel antibodies against specific protein epitopes, it is necessary to generate accurate models of their structure at speed and scale. Key to Exscientia’s AI approach is using the knowledge of the observed human antibody space to optimise biologics for clinical development. Bioinformatics 2021 . References .

Antibody 52

Antibody Bioinformatics Engineer Protein 52

Drug Discovery World

JULY 29, 2022

Scientists from seven research institutions including the University of Oxford and the University of Edinburgh have used pioneering bioinformatic modelling to investigate the molecular interactions of the p53 protein known to give protection against cancers.

Gene 52

Gene DNA Protein Genetics 52

Roots Analysis

AUGUST 28, 2022

Recent advances in multi-omics approaches, including genomics, transcriptomics, proteomics, metabolomics, cytometry and imaging, in combination with bioinformatics and biostatistics, have been translated into several popular bioanalytical platforms, such as next-generation sequencing (NGS), single-cell analysis, flow cytometry and mass spectrometry.

Genome 52

Genome Genomics RNA Genome Project 52

Drug Discovery World

SEPTEMBER 7, 2022

By Ashoka Rajendra , Head of Development & Manufacturing Products at Benchling. From discovery, to lead optimsation, process development, pre-clinical, and even investigational new drug filings, each stage of R&D stands to benefit from AI. . The solution is software, but it’s not that simple .

Scientist 52

Scientist Life Science Antibody Protein 52

pharmaphorum

SEPTEMBER 14, 2020

Through his work at the Wellcome Sanger Institute and Congenica, and involvement with the 100,000 Genomes Project, Charlie has been well placed to see the development of genomics over the years and the promises that it will bring to healthcare. Luckily there have been some encouraging developments in sequencing technology in recent years.

Genome 119

Genome Genomics Medicine Gene 119

pharmaphorum

MARCH 28, 2022

Via its third call for applications, AION and BioMed X aims to entice innovative thinkers to find ways to develop solutions to common pharma challenges by analysing existing antibody therapies to make new efficient and effective therapies using AI. Then, a development stage or optimisation stage occurs.

Pharma Companies 98

Pharma Companies Antibody Protein Development 98

Drug Discovery World

APRIL 21, 2023

BMG LABTECH develops and manufactures innovative, high- quality, and reliable microplate reader instrumentation, while Microtechnix (MTX) is a company providing innovative solutions for biological laboratory assays. On the other hand, Bionomous provide AI-powered solutions for screening, sorting and dispensing of small biological entities.

Doctors 52

Doctors Doctor Genetics In-Vitro 52

The Pharma Data

JANUARY 10, 2021

His company is leveraging the novel cellular immunotherapy development platform he invented to develop novel, targeted, allogeneic cell therapies against cancer with NK cells, the body’s immune cells that specialize in recognizing and attacking cancer cells. Can we develop…almost a preventative therapeutic approach?

Vaccination 52

Vaccination Vaccine Regulation Drugs 52